Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
JACC Cardiovasc Imaging. 2020 Jul;13(7):1521-1530. doi: 10.1016/j.jcmg.2020.01.014. Epub 2020 Mar 18.
The purpose of this study was to examine prognostic value of T1- and T2-mapping techniques in heart transplant patients.
Myocardial characterization using T2 mapping (evaluation of edema/inflammation) and pre- and post-gadolinium contrast T1 mapping (calculation of extracellular volume fraction [ECV] for assessment of interstitial expansion/fibrosis) are emerging modalities that have been investigated in various cardiomyopathies.
A total of 99 heart transplant patients underwent the magnetic resonance imaging (MRI) scans including T1- (n = 90) and T2-mapping (n = 79) techniques. Relevant clinical characteristics, MRI parameters including late gadolinium enhancement (LGE), and invasive hemodynamics were collected. Median clinical follow-up duration after the baseline scan was 2.4 to 3.5 years. Clinical outcomes include cardiac events (cardiac death, myocardial infarction, coronary revascularization, and heart failure hospitalization), noncardiac death and noncardiac hospitalization.
Overall, the global native T1, postcontrast T1, ECV, and T2 were 1,030 ± 56 ms, 458 ± 84 ms, 27 ± 4% and 50 ± 4 ms, respectively. Top-tercile-range ECV (ECV >29%) independently predicted adverse clinical outcomes compared with bottom-tercile-range ECV (ECV <25%) (hazard ratio [HR]: 2.87; 95% confidence interval [CI]: 1.07 to 7.68; p = 0.04) in a multivariable model with left ventricular end-systolic volume and LGE. Higher T2 (T2 ≥50.2 ms) independently predicted adverse clinical outcomes (HR: 3.01; 95% CI: 1.39 to 6.54; p = 0.005) after adjustment for left ventricular ejection fraction, left ventricular end-systolic volume, and LGE. Additionally, higher T2 (T2 ≥50.2 ms) also independently predicted cardiac events (HR: 4.92; CI: 1.60 to 15.14; p = 0.005) in a multivariable model with left ventricular ejection fraction.
MRI-derived myocardial ECV and T2 mapping in heart transplant patients were independently associated with cardiac and noncardiac outcomes. Our findings highlight the need for larger prospective studies.
本研究旨在探讨 T1 和 T2 映射技术在心脏移植患者中的预后价值。
心肌 T2 映射(评估水肿/炎症)和钆对比前后 T1 映射(计算细胞外容积分数 [ECV]以评估间质扩张/纤维化)用于心肌特征描述的技术是新兴技术,已在多种心肌病中进行了研究。
共 99 例心脏移植患者接受了包括 T1(n=90)和 T2 映射(n=79)技术的磁共振成像(MRI)扫描。收集了相关临床特征、MRI 参数(包括晚期钆增强[LGE])和侵入性血液动力学数据。基线扫描后中位临床随访时间为 2.4 至 3.5 年。临床结局包括心脏事件(心脏死亡、心肌梗死、冠状动脉血运重建和心力衰竭住院)、非心脏死亡和非心脏住院。
总体而言,全球固有 T1、对比后 T1、ECV 和 T2 分别为 1030±56ms、458±84ms、27±4%和 50±4ms。与 ECV 下三分位(ECV<25%)相比,ECV 上三分位(ECV>29%)独立预测不良临床结局(危险比[HR]:2.87;95%置信区间[CI]:1.07 至 7.68;p=0.04)。在包含左心室收缩末期容积和 LGE 的多变量模型中。调整左心室射血分数、左心室收缩末期容积和 LGE 后,较高的 T2(T2≥50.2ms)独立预测不良临床结局(HR:3.01;95%CI:1.39 至 6.54;p=0.005)。此外,在包含左心室射血分数的多变量模型中,较高的 T2(T2≥50.2ms)也独立预测心脏事件(HR:4.92;CI:1.60 至 15.14;p=0.005)。
心脏移植患者的 MRI 衍生心肌 ECV 和 T2 映射与心脏和非心脏结局独立相关。我们的研究结果强调了需要进行更大规模的前瞻性研究。